Peripheral Imaging Catheter Market

The global peripheral imaging catheter market was valued at USD 991.4 million in 2025, is estimated at USD 1,053.9 million in 2026, and is forecast to reach USD 1,717.5 million by 2034, a 6.3% CAGR during 2026–2034.

Peripheral imaging catheters are sterile intravascular devices that acquire ultrasound or optical images inside peripheral arteries and veins. Their disposable catheter revenue is counted when the imaging element is integrated into the device used during a peripheral intervention. The estimate excludes stand-alone consoles, coronary-only imaging catheters, diagnostic angiography tubing, conventional ultrasound probes, nonimaging balloons, lithotripsy devices, and hospital procedure charges. Imaging-enabled atherectomy and crossing catheters are included only for the catheter component attributable to peripheral intraluminal imaging.

The American Heart Association estimates that 10 million to 12 million U.S. adults aged 40 and older have peripheral artery disease. Diabetes, smoking, chronic kidney disease and advancing age increase the burden of complex lower-extremity lesions. The 2024 multisociety PAD guideline distinguishes asymptomatic disease, symptomatic claudication, chronic limb-threatening ischemia and acute limb ischemia; only a subset of these patients undergoes catheter-based intervention. Intravascular visualization helps operators assess vessel dimensions and dissections before choosing a balloon or stent.

Philips offers Visions PV catheters across .014, .018 and .035 guidewire pathways, while Boston Scientific markets OptiCross 18 and OptiCross 35 for different vessel sizes. The OptiCross 35 reaches 70 mm maximum diameter penetration and uses a 15 MHz rotating transducer; the smaller OptiCross 18 uses 30 MHz for narrower peripheral arteries. ACIST states that its Kodama IVUS catheter is indicated for peripheral and coronary procedures. These concrete indications distinguish in-scope products from general cardiovascular imaging catalogues.

Clinical adoption is supported by evidence but is not uniform across lesion types. A 2024 study reported 83.8% versus 70.1% one-year primary patency with IVUS-guided versus angiography-guided drug-coated balloon treatment; a later meta-analysis covering 800,452 patients also associated IVUS guidance with lower restenosis and reintervention. Observational designs, case mix and heterogeneous operator experience limit causal extrapolation. Device utilization remains sensitive to reimbursement, catheter pricing, procedural complexity and the availability of compatible consoles and trained vascular specialists.

Source: American Heart Association PAD burden; Boston Scientific OptiCross 35; Philips Visions PV .018; IVUS-guided DCB trial.

The study measures sales of disposable peripheral vascular catheters incorporating intraluminal ultrasound or optical imaging, classified once by each of four mutually exclusive revenue dimensions.

Drivers Impact Analysis*

Restraints Impact Analysis*

*CAGR contribution shows the percentage points each factor adds to or removes from the 6.3% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

Peripheral artery disease prevalence raises the need for detailed lesion assessment

The 2024 American Heart Association guidance estimates 10 million to 12 million U.S. adults aged 40 and older have PAD, with diabetes and chronic kidney disease increasing disease complexity. During femoropopliteal procedures, IVUS identifies lumen diameter, calcification, plaque burden and stent expansion that angiography may underestimate. Clinicians can select device sizes against measured vessel walls rather than relying only on two-dimensional silhouettes. The market effect is concentrated in symptomatic patients undergoing revascularization, not all people diagnosed with PAD.

Controlled studies support intravascular guidance in selected peripheral lesions

A prospective drug-coated balloon trial reported 83.8% primary patency with IVUS guidance versus 70.1% with angiography alone at twelve months. A 2025 meta-analysis of 19 studies involving 800,452 patients associated IVUS with lower binary restenosis and reintervention, although pooled designs differed. Better post-treatment sizing and dissection recognition can encourage clinicians to use imaging in calcified or long lesions. Evidence is strongest for selected femoropopliteal interventions; it does not establish that every peripheral procedure requires an imaging catheter.

Product differentiation broadens the treatable range of peripheral vessels

Boston Scientific specifies 15 MHz for OptiCross 35 and 30 MHz for OptiCross 18, reflecting different depth-resolution trade-offs across iliac and below-knee anatomy. Philips markets Visions PV models compatible with .014, .018 and .035-inch guidewires, providing choices for different crossing strategies. ACIST Kodama adds high-definition IVUS imaging to peripheral workflows. As hospitals standardize imaging platforms, catheter compatibility and procedure time become procurement criteria alongside picture quality, making established installed bases commercially significant. Procurement teams also compare sterile catheter stock and staff readiness.

Per-case economics restrain adoption in lower-volume vascular centers

A peripheral imaging procedure requires a sterile disposable catheter, compatible acquisition equipment, skilled staff and time to interpret cross-sectional images. Catheter cost is incremental to angiography, wires, balloons and stents, and reimbursement differs across countries and facilities. A hospital with high intervention throughput can spread console and training expense across more cases; smaller outpatient laboratories may be less able to do so. The price barrier is most acute where patient payment is high and national coverage does not specifically recognize intravascular guidance.

Clinical uncertainty and access gaps create uneven uptake by lesion category

The 2024 systematic literature review described peripheral IVUS evidence as heterogeneous, dominated by retrospective cohorts and registry analyses. Another 2025 comparison of 246,418 patients found mixed findings for reintervention despite a favorable amputation signal. Across the 2025 study cohorts, results depend on lesion complexity, technique and follow-up duration. Clinicians also weigh access-site injury, imaging-catheter deliverability, vessel tortuosity and operator familiarity before advancing an additional device. These practical constraints keep adoption concentrated in specialist teams treating difficult peripheral anatomy. U.S. hospitals also require dependable catheter inventory and imaging support.

Sources: American Heart Association 2024 PAD guideline; PubMed 38966936, 39674438, 40017153 and 38582216; Philips, Boston Scientific and ACIST product documentation.

Imaging moves from lesion confirmation toward procedural optimization

Operators increasingly use IVUS measurements before choosing balloon diameter and after treatment to identify residual stenosis, malapposition or dissection. The 2024 randomized trial of femoropopliteal drug-coated balloon angioplasty recorded 3.90 mm post-procedure minimum lumen diameter under IVUS guidance versus 3.71 mm with angiography alone. This technical difference illustrates why imaging may influence device selection rather than simply document disease. Repeated catheter passes remain a trade-off, particularly when crossing calcified or narrow peripheral vessels increases procedure complexity.

Different ultrasound frequencies target large and small vascular territories

OptiCross 35 uses a 15 MHz rotating transducer and is specified for iliac, vena cava, femoral and aortic applications, whereas the OptiCross 18 product employs 30 MHz for superficial femoral, popliteal, tibial and renal vessels. Philips offers a .035 catheter with 60 mm imaging diameter and a .018 variant with 24 mm maximum imaging diameter. Such specifications favor catheter selection by vessel size and wire strategy, rather than a single product for every anatomical segment.

Integrated optical guidance supports specialized plaque treatment workflows

Avinger’s Pantheris LV catheter combines peripheral atherectomy with real-time OCT imaging, while Tigereye ST adds image-guided crossing of chronic total occlusions. FDA clearance for Pantheris LV in June 2023 identifies native and restenotic peripheral vessels, including in-stent restenosis, within its intended use. The combined device can visualize the lumen while removing or crossing plaque, but its therapeutic function differs from stand-alone IVUS assessment. Accounting must therefore exclude duplicate console, atherectomy service and imaging catheter revenue.

Evidence synthesis increasingly separates clinical benefit by lesion severity

A 2025 review of 9,873 femoropopliteal patients found higher odds of primary patency and freedom from clinically driven target-lesion revascularization with IVUS guidance. A separate complex-lesion trial reported 82.1% versus 60.3% primary patency, but noncomplex lesions did not show a corresponding advantage. This distinction favors selective adoption in long, calcified or otherwise challenging disease. Additional 2026 randomized comparisons could refine indications and payer decisions. It also limits assumptions that ultrasound imaging will be standard for routine, short, uncomplicated lesions across every care setting.

Peripheral device labels and workflow integration influence supplier competition

Philips received FDA 510(k) K253399 clearance in October 2025 for Visions PV .014P and .018 catheters. Product development emphasizes maintaining guidewire compatibility and catheter performance within established indications. ACIST’s HDi system pairs the Kodama catheter with compact image review and PACS connectivity; Boston Scientific links OptiCross products to its Avvigo platform. Hospitals purchasing one console family may favor its corresponding disposable catheter range, creating a recurring-revenue advantage without requiring manufacturers to sell complete scanners.

Peripheral vascular imaging depends on intraluminal visualization of plaque, vessel boundaries and device placement; ultrasound and optical techniques offer different depth, resolution and procedural workflows.

Intravascular ultrasound is useful when fluoroscopic angiography provides insufficient information about vessel wall morphology. A cross-sectional view can reveal eccentric plaque, calcium distribution, thrombus and stent expansion, supporting more tailored endovascular choices. OptiCross 35 is designed for relatively large peripheral vessels, whereas smaller profiles suit below-knee intervention. A physician still needs angiography for access and device navigation, so intravascular imaging is an adjunct rather than a replacement for all conventional vascular visualization.

Optical coherence tomography offers high-resolution optical assessment but generally requires different image acquisition and tissue penetration characteristics from IVUS. Avinger’s systems use OCT to orient a crossing or atherectomy catheter during treatment, making their commercial model distinct from a separate diagnostic IVUS catheter. These integrated devices can help operators maintain position relative to the vessel wall; they are not equivalent to an OCT catheter approved solely for coronary artery assessment.

A 2025 meta-analysis of femoropopliteal disease included twelve studies and almost ten thousand patients, reporting favorable patency associations with IVUS. Such results may influence vascular specialist preference, although observational studies are vulnerable to selection effects and operator differences. Hospitals continue to weigh procedural risk, patient anatomy, compatible catheter inventory and the incremental cost of imaging when deciding whether to deploy an intravascular device for a particular case.

The catheter type split uses the manufacturer-specified maximum ultrasound imaging penetration depth, with below-70-mm products separated from models capable of 70 mm or more. This classification is based on imaging reach rather than shaft size, guidewire diameter or lesion length. Optical systems are assigned to the relevant penetration category using their labeled capabilities.

Depth categories should be interpreted alongside vessel anatomy, image resolution and procedural approach. High-frequency transducers generally favor detailed smaller-vessel imaging, whereas deeper penetration supports assessment of larger lumens. Hospitals often stock more than one catheter size when treating both arterial and venous disease. The forecast assumes continued product differentiation rather than a sudden convergence on one maximum-penetration specification.

The application axis assigns peripheral imaging catheter revenue to the facility where the device is consumed: hospitals, specialty vascular clinics, ambulatory surgical centers or other procedural facilities. The allocation follows the point of use and does not double count a catheter transferred between departments or procured through a central purchasing group.

Other procedural facilities include smaller office-based laboratories and dedicated day-treatment units not classified elsewhere. Procurement decisions vary with local payment systems and operator preference. The application outlook therefore reflects where interventions are performed, not where PAD is diagnosed or where a referral originates.

Peripheral intravascular imaging is divided into ultrasound and optical coherence tomography according to the sensor integrated into the catheter. For the 2025 revenue allocation, each disposable device is assigned to one primary technology. Conventional angiography and externally applied duplex ultrasound are excluded because their imaging does not originate from a peripheral intraluminal catheter.

The technology split is driven by clinical indication and the design of available products rather than an assumption that one method will replace the other. IVUS has a broad range of peripheral vessel sizes and applications, whereas optical guidance is most distinctive in selected image-guided therapeutic procedures. Future combined-sensor designs would require careful assignment to a primary category to preserve a mutually exclusive market model.

Each peripheral imaging catheter is allocated to the principal disease indication documented for the procedure. The four groups are peripheral artery disease, chronic venous insufficiency, deep vein thrombosis or post-thrombotic disease, and other peripheral vascular lesions. A catheter used during one intervention is counted once even when a patient has multiple comorbidities.

Other peripheral lesions include selected noncoronary vascular pathologies that meet device labeling and use intraluminal imaging. The outlook does not count renal, carotid or cerebral indications excluded from particular device labels. Growth will depend on clinical evidence and procedural selection within each disease category rather than on aggregate prevalence alone.

Peripheral imaging catheter demand differs across regional intervention volumes, reimbursement rules, specialist training and device access. North America leads value, while the largest long-term incremental patient pool lies in Asia-Pacific.

Payment arrangements for peripheral vascular interventions differ by care setting and jurisdiction; catheter cost is borne within a broader episode of vascular treatment.

United States vascular interventions occur in hospital inpatient, outpatient and office-based settings with distinct payment mechanisms. Imaging catheter adoption depends on whether incremental disposable costs are recoverable within the procedure payment or justified by improved device sizing and potential avoidance of repeat interventions. Because not all peripheral lesions need intravascular imaging, local clinical protocols often reserve use for calcified, long, restenotic or technically difficult cases rather than applying a blanket requirement.

European health systems typically negotiate hospital procurement prices and apply diagnosis-related payment frameworks, creating incentives to standardize catheter platforms. German and French specialist centers may adopt image-guided endovascular approaches where outcomes evidence and operator experience support them, while smaller hospitals face greater constraints on capital equipment and consumable inventories. The 2024 ACC/AHA guideline and European PAD practice literature are useful clinical context but should not be misrepresented as mandatory reimbursement coverage for every IVUS catheter.

In Asia-Pacific, a wide range of purchasing models spans advanced Japanese catheterization centers and more price-sensitive public hospitals in India. Operators must account for imported catheter costs, availability of service engineers, training and compatible ultrasound consoles. Private tertiary hospitals may introduce peripheral IVUS before regional public systems, while broader diffusion depends on locally demonstrated clinical utility and predictable procurement budgets. Catheter manufacturers with several guidewire-compatible models can address more vascular territories without claiming that all products share identical regulatory labels. Procurement teams also compare sterile shelf life, imaging-console availability and technician training.

Source: AHA 2024 guideline; ACC PAD guidance; Clinical IVUS review.

Regulatory records establish intended peripheral use and separate imaging products from coronary-only or therapeutic-only catheters.

FDA clearance K253399, dated 28 October 2025, identifies Volcano Corporation under Philips Image Guided Therapy as applicant for Visions PV .014P and .018 digital IVUS catheters. The FDA summary describes their shared indications and technical lineage. This is evidence of a regulated peripheral product family, not proof of a new market entrant or a particular sales volume. Existing 2015 clearances for the .014P, .018 and .035 variants establish a longer commercial history.

Avinger’s June 2023 Pantheris LV clearance covers image-guided atherectomy in peripheral native and restenotic vessels, including in-stent restenosis. Its labeled exclusion of coronary, cerebral, renal and carotid territories is material when assigning peripheral catheter revenue. Terumo’s October 2025 DualView clearance, in contrast, concerns coronary artery disease; it is therefore excluded even though it combines optical frequency domain imaging and ultrasound. Product purpose and labeling determine inclusion rather than manufacturer reputation.

FDA regulatory clearance establishes substantial equivalence rather than comparative clinical superiority. The 2024 AHA guideline recommends evidence-based diagnosis and revascularization selection, while published IVUS studies provide supporting but heterogeneous evidence on outcomes. Future submissions may address deliverability, software and imaging performance; adoption forecasts remain contingent on physician preference and procedure economics. Medical device catalogues and clinical studies can establish products and technical characteristics, but they do not independently verify a manufacturer revenue share.

Commercial supply of peripheral intravascular imaging catheters is concentrated among a small set of independently verified manufacturers with explicit peripheral indications. Their differentiation depends on catheter size, imaging modality, platform compatibility and treatment integration.

Philips benefits from a broad guidewire-compatible product family and an installed base of peripheral imaging equipment. Its product specifications describe 24 mm maximum imaging diameter for Visions PV .018 and 60 mm for the .035 variant. Different profiles permit operators to choose between smaller arteries and larger iliac or venous structures. FDA clearance documents demonstrate continuity of the product line, but do not reveal the company’s share of peripheral catheter revenue.

Boston Scientific competes through rotational ultrasound technology and its OptiCross range. The company’s OptiCross 35 documentation lists 70 mm maximum penetration and 15 MHz operation, with intended uses extending to the aorta and vena cava. OptiCross 18 targets smaller vascular territories at 30 MHz. Hospitals evaluating these devices compare deliverability, wire compatibility, image depth and existing platform contracts rather than assuming that one catheter can serve all lesion types.

ACIST Medical Systems, part of Bracco, markets Kodama with its HDi imaging platform. Company documentation explicitly includes peripheral intervention strategy and highlights the compact console and workflow connectivity. This supplier occupies a differentiated position where facilities want high-definition cross-sectional imaging without changing established catheterization workflows. Avinger instead provides OCT-assisted treatment catheters for peripheral atherectomy and chronic total occlusion crossing; its products combine imaging with a therapeutic function and require separate revenue attribution.

The verified competitive set is deliberately narrower than lists of general cardiovascular device manufacturers. Terumo’s OPUSWAVE DualView product is described by its October 2025 release as a coronary artery device, and coronary-only OCT suppliers do not qualify merely because their systems perform intravascular imaging. Manufacturers selling balloons, lithotripsy or angiography consumables without an intraluminal imaging element are also excluded. Competitive pressure centers on clinical outcomes, specialist training, compatible consoles and the ability to serve distinct peripheral vessel sizes.

• Philips / Volcano Corporation
• Boston Scientific Corporation
• ACIST Medical Systems / Bracco Group
• Avinger, Inc.

Peripheral imaging catheter revenue is forecast to increase from USD 1,053.9 million in 2026 to USD 1,717.5 million by 2034, consistent with a 6.3% CAGR over eight years.

The base-case forecast follows the publisher’s global 2024, 2025 and 2032 monetary points and extends the associated 6.3% annual growth profile through 2034. Revenue refers to peripheral intravascular imaging catheters, not the broader market for angioplasty balloons, IVL, angiography or complete console systems. The largest incremental demand is expected where peripheral vascular intervention volumes grow and clinicians use imaging to guide sizing, assess calcium and verify treatment results. Routine use in every diagnosed PAD patient is not assumed.

North American specialist hospitals should remain the largest value market because of established endovascular infrastructure, availability of peripheral-specific IVUS catheters and ongoing clinical evidence generation. European growth is likely to depend on procurement economics and treatment protocols, while Asia-Pacific adds more procedure volume as tertiary vascular centers expand. Latin America and Middle East & Africa have narrower access to disposable imaging devices, but selective use can increase at referral hospitals with complex limb-salvage programs.

The strongest technology opportunity is to reduce the trade-off between catheter deliverability, vessel coverage and image quality. Small profiles and higher-frequency IVUS suit narrower arteries; lower-frequency large-diameter devices address iliac and venous anatomy. Optical imaging combined with atherectomy or chronic occlusion crossing may retain a specialist niche rather than displacing IVUS across all peripheral indications. Console compatibility and staff training will remain important purchasing factors, particularly for hospitals operating more than one intravascular platform.

Uncertainty comes from reimbursement, heterogeneous comparative studies and differences in lesion selection. A 2025 femoropopliteal meta-analysis found improved patency associations, but evidence cannot be transferred automatically to uncomplicated lesions or all venous indications. Growth could exceed the baseline if new clinical trials demonstrate reproducible reductions in repeat procedures and payers recognize the value of imaging. Conversely, budget pressure or competing device expenditure could slow uptake despite a rising burden of peripheral vascular disease.

Coverage includes the catheter-only revenue chain, device specifications, peripheral clinical evidence and country-level adoption conditions.